ArticlePLoS neglected tropical diseases2023
Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.
Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Survival Analysis in Cutaneous Leishmaniasis Patients: A Retrospective Cohort Study.Biomedicines · 2026Article
- A 10-year registry-based retrospective study of cutaneous Leishmaniasis in Mashhad, northeastern Iran: Demographic, clinical, and therapeutic profiles of 1537 cases.Parasite epidemiology and control · 2026Article
- Clinical, laboratory, and therapeutic characteristics of cutaneous leishmaniasis: 15-year incidence in Crete and Greece, and implications for clinician awareness.GMS hygiene and infection control · 2026Article
- Oral 18-methoxycoronaridine activity in simian and murineFrontiers in pharmacology · 2026Article
- Dosing and safety of amphotericin B deoxycholate in paediatric American cutaneous leishmaniasis in Peru: a case series.BMC infectious diseases · 2025Article
- Evaluation of an Electrospun Fiber Loaded with Ozonated Oil for the Treatment of Leishmaniasis Lesions in an Experimental Model.Journal of arthropod-borne diseases · 2025Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Barbituric Acid Derivatives as Covalent Inhibitors ofJournal of medicinal chemistry · 2025Article
- The Treatment of Acute Cutaneous Leishmaniasis With Oral Zinc Bisglycinate and Oral Hydroxychloroquine Sulfate.Cureus · 2025Article
- Topical Application of Oxylipin (3Journal of natural products · 2025Article
- Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.Clinics and practice · 2025Review
- Nanostructured Lipid Carrier for Intracellular Delivery of a Bis(pyridine-2-carboxamidine) DNA Minor Groove Binder Active againstACS omega · 2025Article
- A Virtual Screening Approach to Evaluate the Multitarget Potential of a Chalcone Library with Binding Properties to Oligopeptidase B and Cysteine Proteinase B fromInternational journal of molecular sciences · 2025Article
- Effectiveness of Antileishmanial Treatments in Three Endemic Areas of Colombia: A Community-Based Cohort Study.The American journal of tropical medicine and hygiene · 2024Article
- Case Report: Cutaneous Leishmaniasis: A Case Series with Intralesional Treatment in Northeast Brazil.The American journal of tropical medicine and hygiene · 2024Article
- Anti-leishmanial effects of Eryngium planum and Ecbilliun elaterum methanolic extract against Leishmania major.AMB Express · 2024Article
- mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study.The American journal of tropical medicine and hygiene · 2023Article
- Article
- Challenges in the treatment of cutaneous leishmaniasis caused byTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 6 countries.
Funding
Abstract
backgroundTreatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.
methodsWe conducted a collaborative retrospective study to describe the effectiveness and safety of antileishmanial treatments in children ≤ 10 and adults ≥ 60 years of age, treated between 2014 and 2018 in ten CL referral centers in Latin America.
results2,037 clinical records were assessed for eligibility. Of them, the main reason for non-inclusion was lack of data on treatment follow-up and therapeutic response (182/242, 75% of children and 179/468, 38% of adults). Data on 1,325 eligible CL patients (736 children and 589 older adults) were analyzed. In both age groups, disease presentation was mild, with a median number of lesions of one (IQR: 1-2) and median lesion diameter of less than 3 cm. Less than 50% of the patients had data for two or more follow-up visits post-treatment (being only 28% in pediatric patients). Systemic antimonials were the most common monotherapy regimen in both age groups (590/736, 80.2% of children and 308/589, 52.3% of older adults) with overall cure rates of 54.6% (95% CI: 50.5-58.6%) and 68.2% (95% CI: 62.6-73.4%), respectively. Other treatments used include miltefosine, amphotericin B, intralesional antimonials, and pentamidine. Adverse reactions related to the main treatment were experienced in 11.9% (86/722) of children versus 38.4% (206/537) of older adults. Most adverse reactions were of mild intensity.
conclusionOur findings support the need for greater availability and use of alternatives to systemic antimonials, particularly local therapies, and development of strategies to improve patient follow-up across the region, with special attention to pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.